Total Funding
1
9
Total FundingPost-IPO Debt raised
Growth Score
-27 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
829490
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
David Walton: Vice President, Marketing & Commercial DevelopmentPast Role: LifeScan, Worldwide Director, Global Strategic Marketing- Patrick Mooney: Founder & CEOPast Role: Echo Therapeutics, CEO, President, Chairman
About the Company
Echo Therapeutics is a medical device company with deep expertise in advanced skin permeation technology. Echo is developing its Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system for use in hospital critical care units and for people with diabetes. The Prelude® SkinPrep System, a component of their Symphony CGM
System, allows for enhanced skin permeation that will enable extraction of analytes, such as glucose, and transdermal drug delivery.
